VERSANT VENTURE MANAGEMENT LLC
Q3 2025 Form 13-F

SAN FRANCISCO, CALIFORNIA
CIK 0001560009 · CRD 161130 · Exempt reporting adviser
$212.5M Reported Value Total

VERSANT VENTURE MANAGEMENT, LLC reports under management (AUM).

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Exempt Reporting Adviser
Source: Form ADV filed 2026-03-30
Reported value
$212.5M
Quarter over quarter
+35.6%
Holdings
9
Top-10 concentration
100.0%

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Max Eisenberg
Chief Operating Officer

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2025 13F record

Q3 2025 13F filing summary

Q3 2025 Form 13F portfolio summary
Period of report September 30, 2025
Filed November 10, 2025
Form 13F-HR
Reported value $212.5M
Positions 9
Change in reported value +158.7%
New positions 1
Exited positions 0
Position turnover 11.1%
Top-10 concentration 100.0%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 13, 2026
8 $109.1M
Q2 2026 13F
Filed Aug 12, 2026
8 $162.6M
Q1 2026 13F
Filed May 5, 2026
8 $141.4M
Q4 2025 13F
Filed Feb 12, 2026
7 $151.1M
Q3 2025 13F
Filed Nov 10, 2025
9 $212.5M
Q2 2025 13F
Filed Aug 11, 2025
8 $82.1M
Q1 2025 13F
Filed May 7, 2025
7 $60.2M
Q4 2024 13F
Filed Feb 12, 2025
7 $86.7M
Q3 2024 13F
Filed Nov 8, 2024
6 $63.6M
Q2 2024 13F
Filed Aug 7, 2024
8 $77.3M
Q1 2024 13F
Filed May 3, 2024
7 $103.1M
Q4 2023 13F
Filed Feb 8, 2024
7 $388.8M
Q3 2023 13F
Filed Nov 3, 2023
8 $188.1M
Q2 2023 13F
Filed Aug 9, 2023
8 $84.3M
Q1 2023 13F
Filed May 11, 2023
7 $48.0M
Q4 2022 13F
Filed Feb 9, 2023
7 $48.3M
Q3 2022 13F
Filed Nov 10, 2022
8 $58.7M
Q2 2022 13F
Filed Aug 11, 2022
8 $65.2M
Q1 2022 13F
Filed May 10, 2022
10 $100.2M
Q4 2021 13F
Filed Feb 11, 2022
10 $187.0M

28 earlier quarters on file — choose one from the quarter menu above.

Top 9 holdings · Q3 2025

Largest Q3 2025 13F positions by reported value
# Holding Reported value % of portfolio
1 LENZ Lenz Therapeutics, Inc. $123.8M 58.25%
2 GLUE Monte Rosa Therapeutics, Inc. $41.9M 19.72%
3 JBIO Jade Biosciences, Inc. $13.2M 6.2%
4 CRSP CRISPR Therapeutics AG $9.6M 4.54%
5 SKYE Skye Bioscience, Inc. $7.9M 3.71%
6 CTNM Contineum Therapeutics, Inc. $6.4M 3.0%
7 RPTX Repare Therapeutics, Inc. $4.7M 2.19%
8 TPST Tempest Therapeutics, Inc. $2.8M 1.31%
9 ADVM Adverum Biotechnologies, Inc. $2.3M 1.08%

Values as reported on the Q3 2025 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings